Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...

Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

After ICIJ’s The Cancer Calculus investigation exposed a market for falsified Keytruda, two sources confirmed Friday that ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...